We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Review Highlights Progress and Validation Needs for AI in Digital Pathology

By LabMedica International staff writers
Posted on 03 Nov 2026

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. More...

Digital pathology based on whole-slide imaging has created a pathway for artificial intelligence to support image-based interpretation. A key challenge is aligning rapidly evolving algorithms with tools that pathologists can reliably use in practice. A new review shows how deep learning technologies can be systematically connected to core clinical pathology tasks.

Researchers at The First Hospital of China Medical University and Northeastern University (Shenyang, China) developed a dual-perspective framework for computational pathology. The framework maps deep learning architectures, including convolutional neural networks, Vision Transformers, and graph neural networks, to clinical applications such as diagnostic classification, tissue segmentation, and prognostic prediction. The review covered developments from 2020 to 2025 and was made available online on July 22, 2026, in the Chinese Medical Journal under the title “Deep learning-based computational pathology: Technologies, clinical applications, and future directions.”

The review describes how advanced artificial intelligence models are being applied to whole-slide imaging data in pathology. Vision Transformers were reported to achieve more than 94% accuracy in classifying oral epithelial dysplasia. Other models can predict cancer patient survival directly from standard hematoxylin and eosin-stained slides, reducing reliance on more expensive and time-consuming genetic tests.

The article also identifies data annotation as a major barrier to the development of artificial intelligence in pathology. Expertly annotated datasets are costly and time-intensive to produce, limiting scalable model training. Emerging weakly supervised and self-supervised learning methods are described as approaches that allow models to learn from large unlabeled datasets and reduce dependence on manual annotation.

The review cites the U.S. Food and Drug Administration (FDA) approval of the Paige Prostate AI system as a signal of progress in digital pathology. It also emphasizes interpretability, regulatory approval, multicenter validation, and equitable implementation as challenges for clinical translation. The authors present computational pathology as a future clinical partner intended to support, rather than replace, pathologists.

“The challenge isn’t just about creating powerful algorithms; it’s about making them clinically relevant and actionable,” said Prof. Xing-hua Gao from The First Hospital of China Medical University. “We introduced a dual-perspective framework that maps specific deep learning architectures—like CNNs, Vision Transformers, and Graph Neural Networks—to essential clinical needs such as diagnostic classification, tissue segmentation, and prognostic prediction. This provides a much-needed roadmap for developing AI solutions that truly address the challenges pathologists face every day.”

“Our goal is to foster the development of AI systems that enhance, rather than replace, the invaluable expertise of pathologists,” said Prof. Xiao-yu Cui from Northeastern University. “This means focusing on critical challenges like model interpretability, ensuring regulatory approval, and validating performance across multiple medical centers. The future lies in creating integrated, trustworthy, and equitable AI that becomes an indispensable partner in clinical decision-making.”

Related Links:
Northeastern University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researcher Joris Deelen (Photo courtesy of Elton Alisson/Agência FAPESP)

Blood-Based Score May Support Targeted Interventions for Healthier Aging

Chronic diseases frequently accumulate with age, complicating efforts to maintain functional independence in older adults. Studies cited by the investigators indicate that about 60% of people over age... Read more

Molecular Diagnostics

view channel
Image: These images show breast tumors in a new preclinical model developed by Garvan researchers. The cells carry a fluorescent sensor that lights up blue/green when CDK1—the protein \'engine\' cells need to divide—is switched on. Using it, the team watched CDK1 activity rise as tumors became invasive and stay high in tumors that kept growing despite treatment. (Image Credit: Dr. Max Nobis / Garvan Institute)

Study Identifies Potential Marker of Targeted Therapy Resistance in Breast Cancer

Estrogen receptor-positive breast cancer is the most common breast cancer subtype and is driven by estrogen. Many patients are treated with CDK4/6 inhibitors alongside hormone therapy, but these drugs... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: The test uses serum or plasma from patients with suspected acute infection and symptoms lasting fewer than seven days and generates a score indicating the likelihood of bacterial infection. (Image Credit: Shutterstock)

Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections

Bacterial and viral infections often cause similar symptoms, making early differentiation difficult in emergency and urgent care settings. Clinicians may need to begin treatment before traditional diagnostic... Read more

Industry

view channel
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.